Aethlon Medical (NASDAQ:AEMD) Now Covered by Analysts at StockNews.com

StockNews.com assumed coverage on shares of Aethlon Medical (NASDAQ:AEMD) in a research report released on Friday morning. The brokerage issued a sell rating on the medical equipment provider’s stock.

Separately, HC Wainwright reaffirmed a “buy” rating and issued a $7.00 price target on shares of Aethlon Medical in a research note on Monday, March 10th.

Aethlon Medical Price Performance

NASDAQ:AEMD opened at $0.37 on Friday. The stock has a market cap of $5.30 million, a PE ratio of -0.23 and a beta of 1.80. Aethlon Medical has a fifty-two week low of $0.24 and a fifty-two week high of $1.79. The stock’s 50-day moving average is $0.56 and its two-hundred day moving average is $0.50.

Aethlon Medical (NASDAQ:AEMD) last announced its quarterly earnings data on Wednesday, February 12th. The medical equipment provider reported ($0.13) EPS for the quarter, beating analysts’ consensus estimates of ($0.22) by $0.09. On average, equities research analysts anticipate that Aethlon Medical will post -0.73 earnings per share for the current year.

Hedge Funds Weigh In On Aethlon Medical

A number of hedge funds have recently added to or reduced their stakes in the company. Renaissance Technologies LLC acquired a new stake in Aethlon Medical in the fourth quarter valued at approximately $25,000. Allegiance Financial Group Advisory Services LLC bought a new position in shares of Aethlon Medical during the 4th quarter valued at $26,000. Sassicaia Capital Advisers LLC bought a new position in shares of Aethlon Medical during the 4th quarter valued at $31,000. Virtu Financial LLC acquired a new stake in shares of Aethlon Medical in the 4th quarter valued at $81,000. Finally, Boothbay Fund Management LLC bought a new stake in Aethlon Medical in the fourth quarter worth $186,000. Institutional investors and hedge funds own 1.99% of the company’s stock.

About Aethlon Medical

Aethlon Medical, Inc, a medical therapeutic company, focuses on developing products to treat cancer and life-threatening infectious diseases in the United States. It develops Hemopurifier, a clinical-stage immunotherapeutic device that removes tumor-derived exosomes and life-threatening viruses and use in organ transplantation.